NCT03609619View on ClinicalTrials.gov

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

PHASE2CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

August 17, 2018

Primary Completion Date

November 23, 2018

Study Completion Date

November 30, 2018

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

AEVI-001

Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.

DRUG

Placebo

Oral doses of Placebo will be administered twice daily, during the treatment period.

Trial Locations (1)

19087

Aevi Genomic Medicine, Wayne

All Listed Sponsors

lead

Aevi Genomic Medicine, LLC, a Cerecor company

INDUSTRY

NCT03609619 - PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations | Biotech Hunter | Biotech Hunter